For information on this past event please contact Meetings Management

Conference Program

Wednesday 10th October 2007

07.30 onwards
Conference Registration

08.55-09.00
Welcome & Opening Remarks
Professor Volker Schirrmacher
CVADD 2007 Conference Chairman

SESSION 1:
OPENING PLENARY SESSION
Moderator: Volker Schirrmacher (DKFZ, Heidelberg, Germany)

09.00-09.30
‘Cancer immunotherapy and tumor immune evasion’
T.-C. Wu (Johns Hopkins University, Baltimore, Maryland, USA)

09.30-10.00
‘DNA fusion gene vaccines: design, delivery and evaluation in cancer patients’
Freda Stevenson (University of Southampton, UK)

10.00-10.30
‘Vaccination in melanoma – past, present and future’
Dirk Schadendorf (DKFZ, Heidelberg, Germany)

10.30-11.00
Coffee & Poster Set-Up

SESSION 2:
PLENARY SESSION
Moderator: Freda Stevenson (University of Southampton, UK)

11.00-11.30
‘The role of myeloid suppressor cells in tumor-induced tolerance and potential therapeutic interventions’
Ivan Borrello (Johns Hopkins University, Baltimore, Maryland, USA)

11.30-12.00
‘Novel approaches to overcome tumor-induced tolerance’
Alexander H. Enk (University of Heidelberg, Germany)

12.00-12.30
‘DNA vaccination in the immunotherapy of cancer’
David B. Weiner (University of Pennsylvania, Philadelphia, USA)

12.30-13.00
‘Transgenic mouse models of spontaneous melanoma for development of new immunotherapies of human melanoma’
Viktor Umansky (DKFZ, Heidelberg, Germany)

13.00-14.00
Lunch & Posters

SESSION 3:
TRIALS
Moderator: Philippe Fournier (DKFZ, Heidelberg, Germany)

14.00-14.30
‘A large-scale, randomised trial of Melacine + low-dose interferon-alfa versus high-dose interferon-alfa in resected stage III melanoma’
Malcolm Mitchell (University of Texas at El Paso, USA)

14.30-15.00
‘ATV-NDV: Concept and clinical experience with a virus-modified autologous tumor cell vaccine’
Volker Schirrmacher (DKFZ, Heidelberg, Germany)

15.00-15.30
‘Gene expression signature associated with clinical response to MAGE-A3 cancer immunotherapeutic in patients with metastatic cutaneous melanoma’
Frederic Lehmann (GSK Biologicals, Rixensart, Belgium)

15.30-15.50
‘Preclinical and clinical results of a novel Ii-key/HER2/neu MHC class II peptide based vaccine in early stage breast cancer (BC) patients’
J.L. Murray, S. Khoo, C.E. Storrer, K.A. Harris, Y.H. Jama, Z.A. Dehqanzada, E.A. Mittendorf, C.D. Shriver, E. von Hofe, S. Ponniah and G.E. Peoples (M.D. Anderson Cancer Center, Houston, Texas, USA)

15.50-16.10
‘New approaches for monitoring CTL activity in cancer vaccine clinical trials’
Anatoli Malyguine (National Cancer Institute-Frederick, Maryland, USA)

16.10-16.30
Tea & Posters

SESSION 4:
CANCER IMMUNOTHERAPY
Moderator: T.-C. Wu (Johns Hopkins University, Baltimore, USA)

16.30-17.00
‘Cancer immunotherapy: keys for development from R&D to registration trials’
Vincent G. Brichard (GSK Biologicals, Rixensart, Belgium)

17.00-17.20
‘Paths from molecularly defined cancer targets to potent immunotherapies’
Ugur Sahin (University of Mainz, Germany)

17.20-17.40
‘Assessment of molecular biomarkers in blood for monitoring patients receiving immunotherapy’
Dave Hoon (John Wayne Cancer Institute, Santa Monica, California, USA)

17.40-18.00
‘Regional lymph nodes in head and neck squamous cell cancer (H&NSCC) and changes induced by IRX-2 immunotherapy’
John Hadden (IRX Therapeutics Inc., New York, USA)

Evening
CVADD 2007 Conference Dinner